Deadline to register is July 21. For more details, visit The IC3 Movement’s 10th Annual Conference and Expo 2026 will be on ...

Permeasis Therapeutics (“Permeasis”), a biotechnology company developing intracellular biologics enabled by its proprietary Membrane Translocation Domain (MTD) platform announced the publication of ...

While many of life's mysteries remain unsolved, every biologist can describe the basic processes performed by a living organism, including energy use, reproduction, growth and development. While these ...

SkinTE® would be the first new biologic commercially available in the U.S. for the treatment of a common chronic wound indication in nearly 30 years, if approved. SkinTE® is a first-in-class ...

In recent years, the concept of postbiotics has gained substantial as an increase of microbiome-based therapies. In contrast to probiotics, postbiotics are ...

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...

What do Botox, rat poison, weight-loss drugs and a fictional murder investigation have in common? At the University of Nevada ...

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of ...

Live biotherapeutics represent an emerging frontier in microbiotechnology, offering novel approaches to treat and prevent ...

The Chicago Venture Summit, Future of Health, will convene investors, founders, academics, researchers, and corporate leaders on October 19 and 20, 2026 CHICAGO, June 25, 2026 /PRNewswire/ -- Today, ...

NDV-01 Phase 2 NMIBC results, Phase 3 mid-2026 outlook, competition, and $160m financing—read the full analysis.

Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events.